Cargando…

Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab

BACKGROUND AND OBJECTIVES: To investigate the longitudinal dynamic of lymphocyte subsets during treatment with ocrelizumab (OCR) in patients with multiple sclerosis (PwMS). METHODS: A multicenter retrospective study was conducted in 161 PwMS starting treatment with OCR grouped in naive (naive, n = 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Landi, Doriana, Grimaldi, Alfonso, Bovis, Francesca, Ponzano, Marta, Fantozzi, Roberta, Buttari, Fabio, Signoriello, Elisabetta, Lus, Giacomo, Lucchini, Matteo, Mirabella, Massimiliano, Cellerino, Maria, Inglese, Matilde, Cola, Gaia, Nicoletti, Carolina Gabri, Mataluni, Giorgia, Centonze, Diego, Marfia, Girolama Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	RESEARCH Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005049/ https://www.ncbi.nlm.nih.gov/pubmed/35273036 http://dx.doi.org/10.1212/NXI.0000000000001157

Ejemplares similares

COVID-19 vaccine hesitancy among Italian people with multiple sclerosis
por: Proietti, Francesca, et al.
Publicado: (2022)

Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis
por: Landi, Doriana, et al.
Publicado: (2020)

Patient’s point of view on the use of telemedicine in multiple sclerosis: a web-based survey
por: Landi, Doriana, et al.
Publicado: (2021)

Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection
por: Landi, Doriana, et al.
Publicado: (2022)

Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy
por: Parisi, Vincenzo, et al.
Publicado: (2023)

Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod
por: Barbano, Lucilla, et al.
Publicado: (2021)

Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells’ Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration
por: Barbano, Lucilla, et al.
Publicado: (2022)

Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment
por: Prezioso, Carla, et al.
Publicado: (2021)

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
por: Abbadessa, Gianmarco, et al.
Publicado: (2021)

T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers
por: Iannetta, Marco, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
por: Iannetta, Marco, et al.
Publicado: (2020)

Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis
por: Stampanoni Bassi, Mario, et al.
Publicado: (2018)

Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis
por: Ziccardi, Lucia, et al.
Publicado: (2020)

Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis
por: Martucci, Alessio, et al.
Publicado: (2021)

Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression
por: Albanese, Maria, et al.
Publicado: (2016)

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
por: Zanghì, Aurora, et al.
Publicado: (2022)

Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
por: Petracca, Maria, et al.
Publicado: (2022)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Interleukin-1β Alters Hebbian Synaptic Plasticity in Multiple Sclerosis
por: Stampanoni Bassi, Mario, et al.
Publicado: (2020)

Optimizing the “Time to pregnancy” in women with multiple sclerosis: the OPTIMUS Delphi survey
por: Carbone, Luigi, et al.
Publicado: (2023)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Remodeling Functional Connectivity in Multiple Sclerosis: A Challenging Therapeutic Approach
por: Stampanoni Bassi, Mario, et al.
Publicado: (2017)

Bridging Therapies With Injectable Immunomodulatory Drugs in the Management of Multiple Sclerosis: A Delphi Survey of an Italian Expert Panel of Neurologists
por: Marfia, Girolama Alessandra, et al.
Publicado: (2022)

Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment
por: Prezioso, Carla, et al.
Publicado: (2022)

Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
por: Tazza, F., et al.
Publicado: (2021)

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
por: Chisari, Clara G., et al.
Publicado: (2023)

Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study
por: Alvino, Bisecco, et al.
Publicado: (2021)

Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study
por: Bisecco, Alvino, et al.
Publicado: (2022)

Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients
por: Stampanoni Bassi, Mario, et al.
Publicado: (2020)

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
por: Novi, Giovanni, et al.
Publicado: (2020)

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
por: Lucchini, Matteo, et al.
Publicado: (2020)

Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
por: Lanzillo, Roberta, et al.
Publicado: (2022)

Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS
por: Novi, Giovanni, et al.
Publicado: (2020)

IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis
por: Stampanoni Bassi, Mario, et al.
Publicado: (2020)

Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis
por: Sparaco, Maddalena, et al.
Publicado: (2023)

Association between Early Neuroretinal Dysfunction and Peripheral Motor Unit Loss in Patients with Type 1 Diabetes Mellitus
por: Picconi, Fabiana, et al.
Publicado: (2018)

Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study
por: Landi, Doriana, et al.
Publicado: (2017)

B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications
por: Iannetta, Marco, et al.
Publicado: (2022)

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
por: Emery, Paul, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p71h7vvstmp2g4mmlm989jartf